Medfinder
Back to blog

Updated: January 12, 2026

How Does Apretude Work? Mechanism of Action Explained in Plain English

Author

Peter Daggett

Peter Daggett

Body silhouette with glowing pathways and medication capsule showing mechanism of action

Apretude (cabotegravir) is an INSTI that blocks HIV's integrase enzyme, stopping the virus from copying itself. Here's a plain-English explanation of how it works.

If you're starting Apretude or considering it, understanding how it works can help you trust the process and stay committed to your injection schedule. The science is genuinely fascinating — and the plain-English version is easier to follow than you might expect.

What Is Cabotegravir?

Apretude's active ingredient is cabotegravir — an antiretroviral drug belonging to the class called Integrase Strand Transfer Inhibitors (INSTIs). Other drugs in this class include dolutegravir (Tivicay), bictegravir (in Biktarvy), and raltegravir (Isentress).

What makes cabotegravir special is its formulation: it's been engineered as an extended-release injectable suspension — meaning the drug is slowly released from the muscle tissue over months, maintaining protective levels in your bloodstream long after the injection.

How HIV Infects Cells (The Setup)

To understand how Apretude works, it helps to understand how HIV infects human cells. HIV is a retrovirus — it carries its genetic code as RNA (not DNA). When HIV enters a CD4 T-cell (an immune cell), it must:

Attach to the cell surface using specific proteins

Fuse with the cell and inject its RNA genetic material

Convert its RNA into DNA (using reverse transcriptase)

Insert (integrate) that viral DNA into the host cell's DNA using an enzyme called integrase

Use the host cell's machinery to produce new HIV copies

Step 4 — the integration step — is where Apretude acts.

How Cabotegravir Blocks HIV: Integrase Inhibition

Cabotegravir specifically blocks the strand transfer step of HIV integration. Here's what happens at the molecular level:

Normally, the integrase enzyme makes cuts in both the host cell's DNA and the viral DNA, then catalyzes the insertion of viral DNA into the host genome (the "strand transfer" step)

Cabotegravir physically binds to the integrase active site — specifically, it chelates the two magnesium ions that integrase needs to function

With integrase disabled, the viral DNA cannot be inserted into the host genome

Without genomic integration, HIV cannot replicate — the infection cycle is broken

This mechanism is well-studied and highly potent. When cabotegravir maintains sufficient blood concentrations, it creates a protective barrier against HIV establishing itself in your cells.

Why the Long-Acting Injection Works So Well

The "extended-release" part of Apretude's name is the engineering triumph. Here's how it works:

Cabotegravir is formulated as a nanosuspension — tiny drug particles suspended in a liquid

When injected into the gluteal muscle, the suspension forms a depot — a slow-release reservoir in the tissue

Cabotegravir dissolves slowly from this depot into the bloodstream over weeks to months

Drug concentrations remain above the threshold needed to inhibit HIV integrase continuously

This is why a single injection every 2 months maintains protection. The drug is continuously present at therapeutic levels — no daily pill required.

The Pharmacokinetic Tail: Why It Matters

Because the drug releases slowly from muscle tissue, cabotegravir continues to circulate in your bloodstream for an extended period after your last injection — up to 12 months or longer. This has two clinical implications:

Good news: The 7-day scheduling flexibility around each injection date works because drug levels remain stable within a 2-month window.

Important caution: After you stop Apretude, residual drug levels may persist for months. If you acquire HIV during this tail phase, those sub-protective levels can drive the virus to develop INSTI resistance. This is why transitioning to oral PrEP within 2 months of stopping Apretude is recommended.

How Apretude Compares to Oral PrEP Mechanistically

Oral PrEP (Truvada/Descovy) works by blocking reverse transcriptase — step 3 in the HIV replication cycle. Apretude works at step 4 (integration). Both are highly effective, but they target different steps in the same process. For a full breakdown of side effects and what to expect, see our guide on Apretude side effects. For help accessing Apretude, visit medfinder.com.

Frequently Asked Questions

Apretude (cabotegravir) is an Integrase Strand Transfer Inhibitor (INSTI). It works by blocking the HIV integrase enzyme, which is required for the virus to insert its genetic material into a host cell's DNA. Without this step, HIV cannot replicate.

Cabotegravir can remain in your bloodstream for up to 12 months or longer after your last Apretude injection. This extended pharmacokinetic tail is a feature of the long-acting formulation — the drug slowly releases from the muscle depot. However, protective levels drop over time, which is why missed injections need to be addressed quickly.

No. Apretude doesn't kill HIV directly. It works by blocking a critical step in HIV's replication cycle — the integrase enzyme that inserts viral DNA into host cell DNA. When this step is blocked, HIV cannot reproduce and establish infection.

Apretude's superior efficacy in clinical trials is largely due to the elimination of daily adherence requirements. Oral PrEP can fail if doses are missed. Since Apretude is administered by a healthcare provider every 2 months, there are far fewer missed-dose opportunities, resulting in more consistent drug levels and better protection.

Apretude is effective against HIV-1, which is the predominant strain worldwide. The key resistance concern is with pre-existing INSTI resistance mutations. HIV testing (including HIV RNA testing in some cases) before each injection is required to catch any new infections early and prevent INSTI resistance development.

Medfinder Editorial Standards

Medfinder's mission is to ensure every patient gets access to the medications they need. We are committed to providing trustworthy, evidence-based information to help you make informed health decisions.

Read our editorial standards

Patients searching for Apretude also looked for:

36,771 have already found their meds with Medfinder.

Start your search today.

36K+
5-star ratingTrusted by 36,771 Happy Patients
      What med are you looking for?
⊙  Find Your Meds
99% success rate
Fast turnaround time
Never call another pharmacy

Need this medication?